Iris Biotechnologies Inc (IRSB) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
5201 GREAT AMERICA PARKWAY SANTA CLARA, CA 95054 |
| State of Incorp. | NY |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2016 MRQ | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 19,839 | 322,929 | 18,988 | 1,042 | |||
| Cash and cash equivalents | 19,839 | 322,929 | 18,988 | 1,042 | |||
| Prepaid expense | 3,625 | 200 | ✕ | ||||
| Other undisclosed current assets | (200) | 14,714 | |||||
| Total current assets: | 23,464 | 322,929 | 18,988 | 15,756 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 29,617 | 8,887 | 4,207 | 8,964 | |||
| Total noncurrent assets: | 29,617 | 8,887 | 4,207 | 8,964 | |||
| TOTAL ASSETS: | 53,081 | 331,816 | 23,195 | 24,720 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 124,298 | 237,014 | 146,044 | 96,803 | |||
| Accounts payable | 237,014 | 146,044 | 96,803 | ||||
| Other undisclosed accounts payable and accrued liabilities | 124,298 | ||||||
| Debt | 5,000 | (45,000) | |||||
| Derivative instruments and hedges, liabilities | 169,082 | ||||||
| Due to related parties | 175,200 | 200 | |||||
| Other undisclosed current liabilities | 90,200 | ||||||
| Total current liabilities: | 468,580 | 242,214 | 191,244 | 96,803 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 26,000 | 26,000 | 16,000 | 47,000 | |||
| Long-term debt, excluding current maturities | 26,000 | 26,000 | 16,000 | 47,000 | |||
| Total noncurrent liabilities: | 26,000 | 26,000 | 16,000 | 47,000 | |||
| Total liabilities: | 494,580 | 268,214 | 207,244 | 143,803 | |||
| Equity | |||||||
| Equity, attributable to parent, including: | (441,499) | 63,602 | (184,049) | (119,083) | |||
| Common stock | 8,850,789 | 8,355,741 | 7,122,546 | 6,791,238 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (128,375) | (128,375) | (128,375) | (128,375) | |||
| Additional paid in capital | 2,878,394 | 2,705,460 | 2,498,986 | 2,409,725 | |||
| Accumulated deficit | (12,042,307) | (10,869,224) | |||||
| Other undisclosed equity, attributable to parent | (9,677,206) | (9,191,671) | |||||
| Total equity: | (441,499) | 63,602 | (184,049) | (119,083) | |||
| TOTAL LIABILITIES AND EQUITY: | 53,081 | 331,816 | 23,195 | 24,720 | |||
Income Statement (P&L) (USD)
| 9/30/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Operating expenses | (1,058,106) | (1,190,304) | (481,150) | (584,328) | ||
| Other undisclosed operating income | 3,324,397 | 3,278,547 | ||||
| Operating income (loss): | (1,058,106) | (1,190,304) | 2,843,247 | 2,694,219 | ||
| Nonoperating expense (Other Nonoperating expense) | (114,977) | |||||
| Income (loss) from continuing operations: | (1,173,083) | (1,190,304) | 2,843,247 | 2,694,219 | ||
| Income (loss) before gain (loss) on sale of properties: | (1,173,083) | (1,190,304) | 2,843,247 | 2,694,219 | ||
| Net income (loss): | (1,173,083) | (1,190,304) | 2,843,247 | 2,694,219 | ||
| Other undisclosed net loss attributable to parent | (1,714) | (3,328,782) | (3,280,169) | |||
| Net loss available to common stockholders, diluted: | (1,173,083) | (1,192,018) | (485,535) | (585,950) | ||
Comprehensive Income (USD)
| 9/30/2016 TTM | 12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (1,173,083) | (1,190,304) | 2,843,247 | 2,694,219 | ||
| Other comprehensive loss | (56,163) | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,229,246) | (1,190,304) | 2,843,247 | 2,694,219 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.